<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Brightgene Bio-medical Technology Co. Ltd. Class A — News on 6ix</title>
<link>https://6ix.com/company/brightgene-bio-medical-technology-c</link>
<description>Latest news and press releases for Brightgene Bio-medical Technology Co. Ltd. Class A on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 16:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/brightgene-bio-medical-technology-c" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836452178dffbe2df150c37.webp</url>
<title>Brightgene Bio-medical Technology Co. Ltd. Class A</title>
<link>https://6ix.com/company/brightgene-bio-medical-technology-c</link>
</image>
<item>
<title>19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities</title>
<link>https://6ix.com/company/brightgene-bio-medical-technology-c/news/193percent-weight-reduction-165-cm-waist-circumference-decrease-sbpdbp-reductions-of-229129-mmhg-707-mmoll-uric-acid-reduction-and-336percent-triglyceride-reduction-bgm0504-demonstrates-comprehensive-cardiometabolic-regulation-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/brightgene-bio-medical-technology-c/news/193percent-weight-reduction-165-cm-waist-circumference-decrease-sbpdbp-reductions-of-229129-mmhg-707-mmoll-uric-acid-reduction-and-336percent-triglyceride-reduction-bgm0504-demonstrates-comprehensive-cardiometabolic-regulation-capabilities</guid>
<pubDate>Wed, 06 May 2026 16:10:00 GMT</pubDate>
<description>Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (CTR20243983/NCT06704581) evaluating its efficacy and safety in participants with overweight or obesity.</description>
</item>
<item>
<title>BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints</title>
<link>https://6ix.com/company/brightgene-bio-medical-technology-c/news/bgm0504-achieves-193percent-robust-weight-reduction-165-cm-waist-circumference-decrease-significant-sbpdbp-improvements-of-229129-mmhg-and-707-mmoll-uric-acid-reduction-phase-iii-trial-meets-primary-endpoint-and-all-key-secondary-endpoints</link>
<guid isPermaLink="true">https://6ix.com/company/brightgene-bio-medical-technology-c/news/bgm0504-achieves-193percent-robust-weight-reduction-165-cm-waist-circumference-decrease-significant-sbpdbp-improvements-of-229129-mmhg-and-707-mmoll-uric-acid-reduction-phase-iii-trial-meets-primary-endpoint-and-all-key-secondary-endpoints</guid>
<pubDate>Tue, 05 May 2026 12:20:00 GMT</pubDate>
<description>BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (Study No.: BGM0504-III-WL) evaluating its efficacy and safety in participants with overweight or obesity. The study successfully met its primary endpoint and</description>
</item>
<item>
<title>BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States</title>
<link>https://6ix.com/company/brightgene-bio-medical-technology-c/news/brightgene-announces-positive-topline-phase-1-results-of-oral-bgm0504-in-obesity-in-china-and-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/brightgene-bio-medical-technology-c/news/brightgene-announces-positive-topline-phase-1-results-of-oral-bgm0504-in-obesity-in-china-and-the-united-states</guid>
<pubDate>Wed, 25 Mar 2026 06:32:00 GMT</pubDate>
<description>BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results from Phase 1 clinical studies of BGM0504, an investigational oral GLP-1/GIP dual receptor agonist, in adult participants in China and the United States, including healthy volunteers and individuals with overweight or obesity.</description>
</item>
<item>
<title>BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions</title>
<link>https://6ix.com/company/brightgene-bio-medical-technology-c/news/brightgene-presents-positive-phase-2-005400013</link>
<guid isPermaLink="true">https://6ix.com/company/brightgene-bio-medical-technology-c/news/brightgene-presents-positive-phase-2-005400013</guid>
<pubDate>Tue, 24 Jun 2025 00:54:00 GMT</pubDate>
<description>BrightGene Pharmaceutical Co., Ltd., an international, innovation-driven pharmaceutical company, presented data from two Phase 2 studies for BGM0504, its investigational dual agonist targeting glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), along with preclinical data for its novel amylin analog, BGM1812, at the 85th Scientific Conference of the American Diabetes Association (ADA).</description>
</item>
</channel>
</rss>